Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02050581 · ClinicalTrials.gov registry record
A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- 72
- Enrollment target
NCT02050581 is a clinical trial that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 72 participants.
The verdict
NCT02050581 was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- 72 participants
- Enrollment target
Study Summary
In this prospective and retrospective chart review, investigators will evaluate the response rates and duration of response for patients with relapsed and refractory idiopathic thrombocytopenic purpura (ITP) who have been treated with rituximab and repeated courses of dexamethasone. Investigators will also evaluate observed toxicities of the combination, and characteristics associated with response.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2011-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02050581
The ClinicalTrials.gov registry entry for NCT02050581 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02050581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02050581 about?
NCT02050581 is a clinical study titled "A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone". In this prospective and retrospective chart review, investigators will evaluate the response rates and duration of response for patients with relapsed and refractory idiopathic thrombocytopenic purpura (ITP) who have been treated with rituximab and repeated courses of dexamethasone. Investigators wi...
What is the current status of trial NCT02050581?
This trial is currently terminated. The enrollment target is 72 participants. The study started on 2011-01.
Who is sponsoring clinical trial NCT02050581?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.